Isis Pharmaceuticals, Inc. (ISIS) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
ISIS Pharmaceuticals (ISIS) Bullish Stance Reiterated at BMO Capital Post Q1
May 8, 2014 6:34 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $70 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) following Q1 results and an update on key initiative. Net loss per share of ($0.27) was slightly wider than the consensus estimate of a loss of... More
Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight
May 6, 2014 3:22 PM EDTPiper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $25.60 yesterday.
... More